Medline (NASDAQ:MDLN) Price Target Lowered to $45.00 at Stifel Nicolaus

Medline (NASDAQ:MDLN) had its price target cut by stock analysts at Stifel Nicolaus from $50.00 to $45.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 27.86% from the company’s previous close.

A number of other research firms also recently issued reports on MDLN. Sanford C. Bernstein decreased their price target on shares of Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Citigroup lowered their price target on shares of Medline from $60.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Barclays decreased their price objective on Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Monday, June 1st. Robert W. Baird decreased their price target on Medline from $57.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, June 3rd. Finally, BNP Paribas Exane dropped their price objective on shares of Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Medline currently has an average rating of “Moderate Buy” and an average target price of $49.42.

Medline Price Performance

Shares of NASDAQ:MDLN traded down $1.48 during trading on Thursday, hitting $35.20. 1,092,740 shares of the company’s stock were exchanged, compared to its average volume of 7,281,322. Medline has a 52-week low of $32.81 and a 52-week high of $50.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.41 and a quick ratio of 2.51. The company has a market cap of $46.24 billion and a price-to-earnings ratio of 109.88. The business’s 50-day simple moving average is $38.29 and its 200 day simple moving average is $41.83.

Medline (NASDAQ:MDLN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.18. The company had revenue of $7.68 billion for the quarter. As a group, equities analysts predict that Medline will post 1.49 EPS for the current year.

Insider Activity

In other Medline news, insider Jessi L. Corcoran acquired 5,000 shares of Medline stock in a transaction that occurred on Friday, June 5th. The stock was bought at an average price of $34.15 per share, with a total value of $170,750.00. Following the completion of the purchase, the insider directly owned 5,000 shares of the company’s stock, valued at approximately $170,750. This represents a ? increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Douglas P. Golwas sold 100,000 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total value of $3,677,000.00. Following the sale, the insider owned 23,899 shares of the company’s stock, valued at approximately $878,766.23. This represents a 80.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Medline

Hedge funds have recently made changes to their positions in the stock. Sound Income Strategies LLC purchased a new position in Medline in the fourth quarter valued at about $25,000. GAMMA Investing LLC boosted its holdings in shares of Medline by 68.3% in the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after buying an additional 254 shares in the last quarter. Entrust Financial LLC purchased a new position in shares of Medline in the 4th quarter worth approximately $26,000. NBC Securities Inc. bought a new position in shares of Medline during the 4th quarter worth approximately $28,000. Finally, Whipplewood Advisors LLC bought a new position in shares of Medline during the 1st quarter worth approximately $30,000.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Revenue growth and adjusted earnings beat expectations. Medline reported second-quarter sales of $7.685 billion, up 11.6% year over year, and adjusted diluted EPS of $0.50 versus the $0.32 consensus estimate. Adjusted EBITDA rose 13.4% to $1.06 billion, supported by existing-customer growth and new customer implementations. Medline Reports Second Quarter and First Six Months 2026 Results
• Positive Sentiment: Medline raised its organic-sales outlook. Management now expects 2026 organic sales growth of 9% to 10%, up from 8.5% to 9.5%, citing strong demand and new customer signings. Operating cash flow increased 28.2% to $1.13 billion in the first half. Medline raises 2026 organic sales outlook
• Positive Sentiment: Analyst support remains bullish. BTIG reiterated a Buy rating and maintained a $55 price target, viewing the company’s growth as durable and the current cost pressures as transitory. Medline BTIG Buy rating and price target
• Neutral Sentiment: The Tracy, California distribution-center fire caused a $336 million loss before expected insurance recoveries. Management characterized the disruption as manageable, but investors may remain focused on execution and recovery timing.
• Negative Sentiment: The key disappointment was guidance. Medline cut its 2026 adjusted EBITDA forecast to $3.3 billion-$3.4 billion from $3.5 billion-$3.6 billion, citing inflation, Middle East-related costs, investments to support demand, quality remediation and retail weakness. GAAP net income fell 58.3% to $139 million, and the quarter benefited from $243 million of tariff refunds, raising concerns about underlying earnings quality. Medline falls despite Q2 beat after EBITDA outlook cut
• Negative Sentiment: A law firm announced an investigation into possible securities-law violations. No findings or formal claims were disclosed, but the announcement adds headline and litigation risk. Kaplan Fox Medline investigation announcement

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.